DBV Technologies (DBVT) - Total Assets
Based on the latest financial reports, DBV Technologies (DBVT) holds total assets worth $223.20 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DBV Technologies - Total Assets Trend (2011–2025)
This chart illustrates how DBV Technologies's total assets have evolved over time, based on quarterly financial data. Also see DBV Technologies stock valuation for the company's overall valuation and market capitalisation.
DBV Technologies - Asset Composition Analysis
Current Asset Composition (December 2025)
DBV Technologies's total assets of $223.20 Million consist of 91.1% current assets and 8.9% non-current assets. Review DBVT liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.1% |
| Accounts Receivable | $16.15 Million | 6.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $22.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how DBV Technologies's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for DBV Technologies for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DBV Technologies's current assets represent 91.1% of total assets in 2025, a decrease from 91.9% in 2011.
- Cash Position: Cash and equivalents constituted 83.1% of total assets in 2025, up from 73.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
DBV Technologies Competitors by Total Assets
Key competitors of DBV Technologies based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
DBV Technologies - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.72 | 2.45 | 3.26 |
| Quick Ratio | 3.72 | 2.45 | 3.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $147.60 Million | $71.82 Million | $76.32 Million |
DBV Technologies - Advanced Valuation Insights
This section examines the relationship between DBV Technologies's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.20 |
| Latest Market Cap to Assets Ratio | 3.36 |
| Asset Growth Rate (YoY) | 256.0% |
| Total Assets | $233.72 Million |
| Market Capitalization | $786.23 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values DBV Technologies's assets at a significant premium (3.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: DBV Technologies's assets grew by 256.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DBV Technologies (2011–2025)
The table below shows the annual total assets of DBV Technologies from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $233.72 Million | +255.96% |
| 2024-12-31 | $65.66 Million | -64.12% |
| 2023-12-31 | $182.99 Million | -25.77% |
| 2022-12-31 | $246.52 Million | +68.48% |
| 2021-12-31 | $146.32 Million | -46.25% |
| 2020-12-31 | $272.25 Million | +0.19% |
| 2019-12-31 | $271.73 Million | +15.75% |
| 2018-12-31 | $234.76 Million | -6.20% |
| 2017-12-31 | $250.28 Million | -21.09% |
| 2016-12-31 | $317.16 Million | -22.56% |
| 2015-12-31 | $409.53 Million | +106.87% |
| 2014-12-31 | $197.96 Million | +133.45% |
| 2013-12-31 | $84.80 Million | +15.64% |
| 2012-12-31 | $73.33 Million | +175.97% |
| 2011-12-31 | $26.57 Million | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more